Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan

Mohamed E. Adam, El Fatih I A Karim, Abdelgader Y. Elkadaru, Kamal E E Ibrahim, Bradley J. Berger, M. Wiese, Hamza A. Babiker

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The effect of imipramine on reversal of chloroquine (CQ) resistance was examined in 40 Plasmodium falciparum patients in Sudan. Parasites were considered resistant if it was still present in peripheral blood on day 3 following treatment with a standard dose of CQ (25mg/Kg body weight), early treatment failure (ETF). Patients proven to be infected with CQ resistant parasites were then given imipramine HCl (100 mg, in two divided doses), on day 3 following chloroquine treatment, for 3 days. Imipramine reversed CQ resistance, within 3 days, in all patients (cure rate of 100%), with mild to moderate side effects. The plasma level of CQ three hours after the initial dose (10mg/Kg body weight), was higher in patients with sensitive parasites (0.649 ± 0.04 × 10 -6mol/L) than in those with resistant parasites (0.585 ± 0.043 × 10 -6mol/L). However, this situation was reversed following imipramine administration, the CQ plasma levels in patients with resistant parasites (0.645 ± 0.089 × 10 -6mol/L) becoming significantly higher (P <0.05) than in patients with sensitive parasites (0.397 ± 0.032 × 10 -6mol/L). The CQ plasma levels remained higher among the group infected with resistant P. falciparum on day 7 compared to the chloroquine sensitive group. The treatment regimen used was well tolerated, and the plasma concentration of imipramine and desipramine in treated patients accorded with that reported for in vitro reversal of CQ resistance.

Original languageEnglish
Pages (from-to)130-135
Number of pages6
JournalSaudi Pharmaceutical Journal
Volume12
Issue number4
Publication statusPublished - Oct 2004

Fingerprint

Sudan
Imipramine
Chloroquine
Plasmodium falciparum
Malaria
Parasites
Body Weight
Desipramine
Treatment Failure
Therapeutics

Keywords

  • Chloroquine
  • HPLC
  • Imipramine
  • Resistance
  • Reversal

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Adam, M. E., Karim, E. F. I. A., Elkadaru, A. Y., Ibrahim, K. E. E., Berger, B. J., Wiese, M., & Babiker, H. A. (2004). Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan. Saudi Pharmaceutical Journal, 12(4), 130-135.

Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan. / Adam, Mohamed E.; Karim, El Fatih I A; Elkadaru, Abdelgader Y.; Ibrahim, Kamal E E; Berger, Bradley J.; Wiese, M.; Babiker, Hamza A.

In: Saudi Pharmaceutical Journal, Vol. 12, No. 4, 10.2004, p. 130-135.

Research output: Contribution to journalArticle

Adam, ME, Karim, EFIA, Elkadaru, AY, Ibrahim, KEE, Berger, BJ, Wiese, M & Babiker, HA 2004, 'Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan', Saudi Pharmaceutical Journal, vol. 12, no. 4, pp. 130-135.
Adam ME, Karim EFIA, Elkadaru AY, Ibrahim KEE, Berger BJ, Wiese M et al. Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan. Saudi Pharmaceutical Journal. 2004 Oct;12(4):130-135.
Adam, Mohamed E. ; Karim, El Fatih I A ; Elkadaru, Abdelgader Y. ; Ibrahim, Kamal E E ; Berger, Bradley J. ; Wiese, M. ; Babiker, Hamza A. / Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan. In: Saudi Pharmaceutical Journal. 2004 ; Vol. 12, No. 4. pp. 130-135.
@article{f1fe21de6ab64b6f8e299146b14f22d2,
title = "Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan",
abstract = "The effect of imipramine on reversal of chloroquine (CQ) resistance was examined in 40 Plasmodium falciparum patients in Sudan. Parasites were considered resistant if it was still present in peripheral blood on day 3 following treatment with a standard dose of CQ (25mg/Kg body weight), early treatment failure (ETF). Patients proven to be infected with CQ resistant parasites were then given imipramine HCl (100 mg, in two divided doses), on day 3 following chloroquine treatment, for 3 days. Imipramine reversed CQ resistance, within 3 days, in all patients (cure rate of 100{\%}), with mild to moderate side effects. The plasma level of CQ three hours after the initial dose (10mg/Kg body weight), was higher in patients with sensitive parasites (0.649 ± 0.04 × 10 -6mol/L) than in those with resistant parasites (0.585 ± 0.043 × 10 -6mol/L). However, this situation was reversed following imipramine administration, the CQ plasma levels in patients with resistant parasites (0.645 ± 0.089 × 10 -6mol/L) becoming significantly higher (P <0.05) than in patients with sensitive parasites (0.397 ± 0.032 × 10 -6mol/L). The CQ plasma levels remained higher among the group infected with resistant P. falciparum on day 7 compared to the chloroquine sensitive group. The treatment regimen used was well tolerated, and the plasma concentration of imipramine and desipramine in treated patients accorded with that reported for in vitro reversal of CQ resistance.",
keywords = "Chloroquine, HPLC, Imipramine, Resistance, Reversal",
author = "Adam, {Mohamed E.} and Karim, {El Fatih I A} and Elkadaru, {Abdelgader Y.} and Ibrahim, {Kamal E E} and Berger, {Bradley J.} and M. Wiese and Babiker, {Hamza A.}",
year = "2004",
month = "10",
language = "English",
volume = "12",
pages = "130--135",
journal = "Saudi Pharmaceutical Journal",
issn = "1319-0164",
publisher = "King Saud University",
number = "4",

}

TY - JOUR

T1 - Imipramine induced complete reversal of chloroquine resistance in Plasmodium falciparum infections in Sudan

AU - Adam, Mohamed E.

AU - Karim, El Fatih I A

AU - Elkadaru, Abdelgader Y.

AU - Ibrahim, Kamal E E

AU - Berger, Bradley J.

AU - Wiese, M.

AU - Babiker, Hamza A.

PY - 2004/10

Y1 - 2004/10

N2 - The effect of imipramine on reversal of chloroquine (CQ) resistance was examined in 40 Plasmodium falciparum patients in Sudan. Parasites were considered resistant if it was still present in peripheral blood on day 3 following treatment with a standard dose of CQ (25mg/Kg body weight), early treatment failure (ETF). Patients proven to be infected with CQ resistant parasites were then given imipramine HCl (100 mg, in two divided doses), on day 3 following chloroquine treatment, for 3 days. Imipramine reversed CQ resistance, within 3 days, in all patients (cure rate of 100%), with mild to moderate side effects. The plasma level of CQ three hours after the initial dose (10mg/Kg body weight), was higher in patients with sensitive parasites (0.649 ± 0.04 × 10 -6mol/L) than in those with resistant parasites (0.585 ± 0.043 × 10 -6mol/L). However, this situation was reversed following imipramine administration, the CQ plasma levels in patients with resistant parasites (0.645 ± 0.089 × 10 -6mol/L) becoming significantly higher (P <0.05) than in patients with sensitive parasites (0.397 ± 0.032 × 10 -6mol/L). The CQ plasma levels remained higher among the group infected with resistant P. falciparum on day 7 compared to the chloroquine sensitive group. The treatment regimen used was well tolerated, and the plasma concentration of imipramine and desipramine in treated patients accorded with that reported for in vitro reversal of CQ resistance.

AB - The effect of imipramine on reversal of chloroquine (CQ) resistance was examined in 40 Plasmodium falciparum patients in Sudan. Parasites were considered resistant if it was still present in peripheral blood on day 3 following treatment with a standard dose of CQ (25mg/Kg body weight), early treatment failure (ETF). Patients proven to be infected with CQ resistant parasites were then given imipramine HCl (100 mg, in two divided doses), on day 3 following chloroquine treatment, for 3 days. Imipramine reversed CQ resistance, within 3 days, in all patients (cure rate of 100%), with mild to moderate side effects. The plasma level of CQ three hours after the initial dose (10mg/Kg body weight), was higher in patients with sensitive parasites (0.649 ± 0.04 × 10 -6mol/L) than in those with resistant parasites (0.585 ± 0.043 × 10 -6mol/L). However, this situation was reversed following imipramine administration, the CQ plasma levels in patients with resistant parasites (0.645 ± 0.089 × 10 -6mol/L) becoming significantly higher (P <0.05) than in patients with sensitive parasites (0.397 ± 0.032 × 10 -6mol/L). The CQ plasma levels remained higher among the group infected with resistant P. falciparum on day 7 compared to the chloroquine sensitive group. The treatment regimen used was well tolerated, and the plasma concentration of imipramine and desipramine in treated patients accorded with that reported for in vitro reversal of CQ resistance.

KW - Chloroquine

KW - HPLC

KW - Imipramine

KW - Resistance

KW - Reversal

UR - http://www.scopus.com/inward/record.url?scp=11144339525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144339525&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 130

EP - 135

JO - Saudi Pharmaceutical Journal

JF - Saudi Pharmaceutical Journal

SN - 1319-0164

IS - 4

ER -